Akarapong Chairean
- Inventiva (NASDAQ:IVA) on Monday said that it secured financing of immediately €94.1 million and up to €348 million to fund the completion of the NATiV3 Phase III MASH trial and preparation for the potential filing for marketing approval and commercialization of lanifibranor.
- The transaction was led by New Enterprise Associates, BVF Partners LP and Samsara BioCapital, with the participation of additional existing and new investors.
- Source: Press Release
